Elabela is a reliable biomarker for predicting early onset preeclampsia: A comparative study

doi:10.12998/wjcc.v11.i17.3993

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 17

This Article

(157)

(172)

(0)

(8)

(1)

(5137)

(3)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Control Study

World J Clin Cases. Jun 16, 2023; 11(17): 3993-4002
Published online Jun 16, 2023. doi: 10.12998/wjcc.v11.i17.3993

Full Size Figure Download Figure

Figure 2 A three-dimensional figures showing the inverse correlation relationship between serum elabela with mean arterial blood pressure and the positive correlation with gestational age. It can be noted seen that the lowest serum elabela is seen at 27-33 wk; early onset preeclampsia. GA: Gestational age; MAP: Mean arterial blood pressure.

Citation: Amer Ali E, Nori W, Salman AF, Al-Rawi TSS, Hameed BH, Al-Ani RM. Elabela is a reliable biomarker for predicting early onset preeclampsia: A comparative study. World J Clin Cases 2023; 11(17): 3993-4002
URL: https://www.wjgnet.com/2307-8960/full/v11/i17/3993.htm
DOI: https://dx.doi.org/10.12998/wjcc.v11.i17.3993

Amer Ali E, Nori W, Salman AF, Al-Rawi TSS, Hameed BH, Al-Ani RM. Elabela is a reliable biomarker for predicting early onset preeclampsia: A comparative study. World J Clin Cases 2023; 11(17): 3993-4002 [PMID: 37388778 DOI: 10.12998/wjcc.v11.i17.3993]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.